Hemophilia A

Hemophilia A is an inherited, X-linked recessive bleeding disorder caused by a deficiency or dysfunction of coagulation factor VIII (FVIII). It is the most common inherited coagulopathy in dogs and cats, characterized by a tendency to spontaneous or trauma-induced hemorrhage into soft tissues, joints, and body cavities. The severity of clinical signs correlates with residual FVIII activity: severe (<1% of normal), moderate (1-5%), and mild (5-40%). Affected animals typically present with excessive bleeding after minor trauma, surgery, or during tooth eruption. The disease is seen predominantly in males, while females are carriers and usually asymptomatic. Hemophilia A is the veterinary counterpart of human hemophilia A and serves as a model for studying the condition.

Hemophilia A is caused by mutations in the F8 gene located on the X chromosome. Over 100 distinct mutations have been identified in dogs, including missense, nonsense, splice-site, and large deletions. These mutations lead to reduced or absent synthesis of functional FVIII protein. In cats, similar mutations have been reported. The disease is inherited in an X-linked recessive pattern: a male with one affected X chromosome is affected; a female with two affected X chromosomes is affected (rare); a female with one affected X chromosome is a carrier and typically has normal or mildly reduced FVIII levels. Spontaneous mutations can also occur, leading to sporadic cases without a known family history. The molecular defect results in impaired intrinsic pathway coagulation, as FVIII is a critical cofactor for factor IXa-mediated activation of factor X.

Hemophilia A is the most common inherited coagulation disorder in dogs and cats. In dogs, it has been reported in many breeds, including German Shepherd Dogs, Golden Retrievers, Labrador Retrievers, Beagles, Pembroke Welsh Corgis, and mixed breeds. In cats, it is less common but has been documented in domestic shorthair and longhair cats. The disease is X-linked, so the majority of affected animals are males. Carrier females are usually asymptomatic but can have mildly reduced FVIII levels. The prevalence is estimated at 1 in 10,000 to 1 in 100,000 in the general canine population, but higher in certain breeds due to founder effects. There is no geographic or seasonal predilection. The condition is often recognized in young animals, typically before 1 year of age, when trauma or surgery triggers bleeding.

Factor VIII is a large glycoprotein synthesized primarily in the liver sinusoidal endothelial cells and, to a lesser extent, in other tissues. It circulates in plasma bound to von Willebrand factor (vWF), which stabilizes it. In the intrinsic coagulation cascade, FVIII is activated by thrombin or factor Xa to FVIIIa, which then acts as a cofactor for factor IXa in the tenase complex, accelerating the activation of factor X. Deficiency of FVIII leads to impaired thrombin generation and fibrin clot formation, resulting in a bleeding tendency. The severity of bleeding correlates with the residual FVIII activity. In severe cases, spontaneous hemorrhages occur into joints (hemarthrosis), muscles, and body cavities. The pathophysiology involves defective primary hemostasis (platelet plug formation is normal) but defective secondary hemostasis (fibrin clot formation). Recurrent bleeding into joints leads to chronic inflammatory changes, synovial hyperplasia, and eventually degenerative joint disease.

The primary predisposing factor is genetic: being male and having a family history of the disease. Breeds with a known high prevalence include German Shepherd Dogs, Golden Retrievers, and Pembroke Welsh Corgis. Environmental factors that precipitate bleeding episodes include trauma, surgery, dental procedures, and parturition. Concurrent conditions that may exacerbate bleeding include infections, liver disease, and the use of medications that interfere with hemostasis, such as non-steroidal anti-inflammatory drugs (NSAIDs) and anticoagulants. Stress and strenuous exercise may also increase the risk of spontaneous bleeding. In carriers, stress or pregnancy may lower FVIII levels, but they rarely bleed spontaneously.

Clinical signs vary depending on the severity of FVIII deficiency. In severe cases, spontaneous bleeding may occur without obvious trauma. Common signs include: lameness due to hemarthrosis (especially in weight-bearing joints), subcutaneous hematomas, muscle bruising, prolonged bleeding from wounds or after surgery, epistaxis, hematuria, melena, and bleeding from the oral cavity during tooth eruption. In severe cases, bleeding into body cavities (thorax, abdomen) can cause respiratory distress, abdominal distension, and shock. In mild cases, bleeding may only occur after significant trauma or surgery. Physical examination may reveal pale mucous membranes, tachycardia, tachypnea, and signs of pain or swelling over affected joints or muscles. Neurologic signs may occur if bleeding into the central nervous system occurs, though this is rare.

Differential diagnoses for Hemophilia A include: 1) Hemophilia B (factor IX deficiency) – clinically indistinguishable, differentiated by specific factor assays. 2) von Willebrand disease (vWD) – typically causes mucosal bleeding and prolonged bleeding time; vWF levels are low. 3) Other inherited coagulopathies such as factor VII deficiency, factor X deficiency, and factor XI deficiency – rare, differentiated by specific factor assays. 4) Acquired coagulopathies such as vitamin K deficiency or rodenticide toxicity – characterized by prolonged PT and aPTT, and response to vitamin K therapy. 5) Disseminated intravascular coagulation (DIC) – associated with underlying disease, thrombocytopenia, and elevated fibrin degradation products. 6) Thrombocytopenia – causes petechiae and mucosal bleeding, but coagulation times are normal. 7) Liver disease – causes multiple factor deficiencies, with prolonged PT and aPTT, and abnormal liver function tests. 8) Vasculitis – causes petechiae and ecchymoses, but coagulation tests are normal. 9) Trauma – may cause bleeding but coagulation tests are normal. 10) Neoplasia – may cause bleeding due to invasion or consumption of coagulation factors.

The diagnostic approach begins with a thorough history and physical examination, focusing on bleeding episodes and family history. Initial screening tests include a complete blood count (CBC), platelet count, buccal mucosal bleeding time (BMBT), prothrombin time (PT), activated partial thromboplastin time (aPTT), and thrombin time (TT). In Hemophilia A, the platelet count and BMBT are normal, PT and TT are normal, but aPTT is prolonged. If aPTT is prolonged, specific factor assays for FVIII and FIX should be performed to differentiate Hemophilia A from Hemophilia B. A definitive diagnosis is made by measuring FVIII activity using a one-stage clotting assay or chromogenic assay. Carrier testing can be performed by measuring FVIII activity (carriers may have reduced levels) or by genetic testing (DNA analysis) for known mutations. Genetic testing is particularly useful for identifying carriers and for breeding decisions.

Hematology: CBC may show anemia if significant blood loss has occurred; platelet count is normal. Coagulation profile: aPTT is prolonged, PT and TT are normal. Specific factor assays: FVIII activity is reduced (severe <1%, moderate 1-5%, mild 5-40%). FIX activity is normal. Serum biochemistry: may be normal unless there is concurrent organ damage or blood loss. Urinalysis: may show hematuria if bleeding into the urinary tract. Blood gas analysis: may reveal metabolic acidosis if shock is present. Specific biomarkers: not routinely used. Genetic testing: DNA analysis can identify specific F8 gene mutations.

Radiography: May show soft tissue swelling, joint effusion, or signs of degenerative joint disease in chronic cases. Thoracic radiographs may reveal pleural effusion if hemothorax is present. Abdominal radiographs may show organomegaly or free fluid. Ultrasonography: Useful for detecting joint effusion, soft tissue hematomas, and abdominal or thoracic fluid accumulation. Echocardiography: Not directly relevant but may be used to assess cardiac function if anemia is severe. CT/MRI: May be used to evaluate intracranial bleeding or deep muscle hematomas. Endoscopy: Not typically indicated.

Cytology: Joint fluid analysis in hemarthrosis typically shows a hemorrhagic effusion with increased red blood cells and possibly inflammatory cells. Histopathology: Not typically performed for diagnosis, but if a biopsy is taken from a bleeding site, it may show hemorrhage and tissue disruption. In chronic hemarthrosis, synovial hyperplasia, hemosiderin deposition, and fibrosis may be seen.

Treatment of acute bleeding episodes involves replacement of FVIII. In veterinary medicine, fresh frozen plasma (FFP) or cryoprecipitate is commonly used. FFP is given at a dose of 10-20 ml/kg IV, repeated every 8-12 hours as needed. Cryoprecipitate is more concentrated and can be given at a lower volume (1 unit per 10 kg). For severe bleeding, human recombinant FVIII (e.g., Advate) can be used, but it is expensive and may not be readily available. Supportive care includes rest, cold packs on affected joints, and analgesics (avoid NSAIDs). In cases of severe anemia, blood transfusion may be necessary. For long-term management, avoiding trauma and elective surgery is crucial. If surgery is unavoidable, pre-operative FVIII replacement is required. Desmopressin (DDAVP) may be used in mild cases to release endogenous FVIII, but its efficacy is variable. Antifibrinolytic agents such as tranexamic acid (10-15 mg/kg PO q8h) or aminocaproic acid (50-100 mg/kg PO q8h) may be used as adjuncts.

The prognosis depends on the severity of the disease. Animals with severe Hemophilia A have a guarded prognosis due to the risk of spontaneous, life-threatening bleeding. With prompt and appropriate treatment, many bleeding episodes can be managed, but the long-term prognosis is poor due to recurrent bleeding and the development of chronic joint disease. Animals with mild to moderate disease may have a better prognosis and can live relatively normal lives with careful management. The prognosis is also influenced by the availability of blood products and the owner's ability to provide intensive care. Carrier females have a normal lifespan.

Follow-up care involves regular monitoring of FVIII levels, especially before and after surgical procedures. Owners should be educated on recognizing early signs of bleeding and seeking immediate veterinary care. For animals with recurrent hemarthrosis, regular joint assessments and management of chronic pain are important. Genetic counseling for breeders is essential to prevent the spread of the disease. Serial aPTT measurements can be used to monitor the response to treatment. In animals receiving repeated FVIII replacement, monitoring for the development of inhibitors (antibodies against FVIII) is recommended, as this can complicate treatment.

Pearls: 1) Always consider Hemophilia A in a young male dog or cat with unexplained bleeding or prolonged aPTT. 2) A normal platelet count and BMBT with prolonged aPTT strongly suggest a factor VIII or IX deficiency. 3) Fresh frozen plasma is the most readily available treatment; cryoprecipitate is preferred if available. 4) Avoid NSAIDs and other drugs that impair platelet function. 5) Genetic testing is invaluable for carrier detection. Pitfalls: 1) Failing to differentiate Hemophilia A from Hemophilia B without specific factor assays. 2) Using vitamin K therapy in Hemophilia A, which is ineffective. 3) Administering excessive fluids that may dilute clotting factors. 4) Performing surgery without adequate factor replacement. 5) Overlooking the possibility of inhibitors after repeated transfusions.

1) Fresh Frozen Plasma (FFP): 10-20 ml/kg IV, repeat every 8-12 hours as needed. 2) Cryoprecipitate: 1 unit per 10 kg IV, repeat as needed. 3) Human recombinant FVIII (e.g., Advate): 50-100 IU/kg IV, repeat every 12 hours as needed. 4) Desmopressin (DDAVP): 1-4 mcg/kg SC or IV, may be used in mild cases. 5) Tranexamic acid: 10-15 mg/kg PO q8h for 3-5 days. 6) Aminocaproic acid: 50-100 mg/kg PO q8h for 3-5 days. 7) For pain management, avoid NSAIDs; use opioids (e.g., buprenorphine 0.01-0.02 mg/kg IV/IM q8-12h) or gabapentin (10-20 mg/kg PO q8-12h). 8) For severe anemia, packed red blood cells (10-20 ml/kg IV) may be administered. 9) In cases of shock, crystalloids (e.g., Lactated Ringer's solution) at 60-90 ml/kg IV bolus, then 10-20 ml/kg/hr. 10) Always monitor for volume overload and transfusion reactions.

Hemophilia A is well-documented in veterinary literature. Studies have characterized the molecular basis of the disease in various breeds, including German Shepherd Dogs and Golden Retrievers. Treatment protocols using FFP and cryoprecipitate are standard, but the efficacy of human recombinant FVIII has been demonstrated in experimental settings. Desmopressin has been shown to increase FVIII levels in some dogs, but its use is controversial. The ACVIM consensus statement on coagulation disorders provides guidelines for diagnosis and management. Recent research has focused on gene therapy, which has shown promise in canine models. Overall, the evidence supports early diagnosis, aggressive treatment of bleeding episodes, and genetic counseling to reduce the prevalence of the disease.